Several multikinase inhibitors such as imatinib, dasatinib, and crizotinib that target several RTKs, including KIT, PDGFRs, and ALK, have been tested in clinical trials for high-risk NB treatment (clinical trials: NCT02559778, NCT00030667, NCT01467986, NCT00788125, NCT00939770, and NCT03126916). Here, ALK is linked to neuroblastoma.